middle.news
Biotron Navigates EMA Feedback on SedRx and Expands Antiviral Research
10:46am on Tuesday 21st of July, 2026 AEST
•
Healthcare
Read Story
Biotron Navigates EMA Feedback on SedRx and Expands Antiviral Research
10:46am on Tuesday 21st of July, 2026 AEST
Key Points
EMA rejects Hybrid MAA pathway for SedRx
Plans for pivotal clinical trials underway
BIT-HBV001 shows promise against Hepatitis Delta Virus
R&D tax rebate of $525,869 received
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Biotron (ASX:BIT)
OPEN ARTICLE